Travere Therapeutics opened lower at $51.79, compared with its previous close of $52.04. In the last trading session, the stock traded between $51.11 and $52.52. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Travere Therapeutics is now worth
$ 171.75
Giving a profit of
$ 71.75 (71.75%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
90.91%
Hold
9.09%
Sell
0%
Markets Today
Today's Change
$-0.46 (-0.89%)
Day High
$52.52
Day Low
$51.11
Day Open
$51.79
Prev Close
$52.04
Volume
4,25,952
1W Return
-1.43%
1M Return
-0.84%
3M Return
-14.38%
6M Return
18.54%
1Y Return
42.83%
Fundamentals
Market Cap ($ Mn)
4,951
PE Ratio
-
PB Ratio
252.12
PEG Ratio
-
ROE
-80.28%
ROCE
-12.98%
EPS (TTM)
$-0.55
Investment Returns
1 Week
-1.43%
1 Month
-0.84%
3 Months
-14.38%
6 Months
18.54%
9 Months
70.67%
Financials
Quarterly
All values in $ Mn
114.4
Jun 25
164.9
Sep 25
129.7
Dec 25
127.2
Mar 26
169.6
Jun 26
224.6
Sep 26
Updates
6Nov
Leerink Partners lowers Travere Therapeutics price target to $67
Leerink Partners lowered Travere Therapeutics' price target from $78 to $67. Analyst Joseph Schwartz maintained an Outperform rating on the stock. The revision reflects updated valuation assumptions for the biotech firm.
7 days ago
5Nov
Canaccord Genuity raises Travere Therapeutics price target to $72
Canaccord Genuity maintains Buy rating on Travere Therapeutics. Price target raised from $70 to $72. Analyst Edward Nash issued the updated recommendation.
8 days ago
4Nov
Guggenheim maintains Buy on Travere Therapeutics, cuts target to $78
Guggenheim maintains a Buy rating on Travere Therapeutics. Price target lowered from $89 to $78. Analyst Vamil Divan authored the rating revision.
8 days ago
3Nov
Travere Therapeutics Q3FY26 Results: Net product sales up 120% YoY to $200.2 million
Total U.S. net product sales reached $220.2 million, a record high for the quarter. FILSPARI U.S. net product sales grew 120% YoY to $200.2 million. Cash and marketable securities stood at $471.8 million as of September 30, 2026. R&D and SG&A expenses were $168.7 million, including $23.8 million in non-cash items. New patient start forms for FILSPARI totaled 1,932 across IgA nephropathy and FSGS.
10 days ago
2Oct
Travere to present new FILSPARI data supporting IgAN and FSGS treatment
Travere Therapeutics presents nine new data sets on FILSPARI at ASN Kidney Week 2026. SPARTAN trial shows 75% complete proteinuria remission in IgAN patients using first-line therapy. DUPLEX analysis reveals 3x higher remission rates and 75% lower kidney failure rates vs irbesartan in FSGS. FILSPARI demonstrated superior eGFR preservation with -3.7 vs -6.2 mL/min/1.73 m²/year chronic slope in FSGS.
1mo ago
22Sep
Travere Therapeutics appoints Bradley Campbell as next CEO
Bradley L. Campbell appointed president and CEO of Travere Therapeutics. Effective date for new leadership is December 1, 2026. Eric Dube steps down to focus on health and family priorities. Dube remains as executive advisor through February 15, 2027.
